Novo Nordisk stock news
On July 31, 2026, the 100% Section 232 tariff on patented pharmaceutical imports officially went into effect for 17 major drugmakers, including Novo Nordisk (NVO). This regulatory shift, part of a broader U.S. onshoring initiative, significantly increases the landed cost of active pharmaceutical ingredients (APIs) and finished drugs imported into the United States. While Novo Nordisk has previously announced a $4.1 billion expansion of its Clayton, North Carolina facility to mitigate long--term supply chain risks, the immediate implementation of these tariffs is expected to pressure margins and necessitate a reassessment of pricing strategies for its GLP--1 franchise, including Wegovy and Ozempic.